1- Ahmed Aziz Bousfiha, Leila Jedam, Fatima Ailal, Waleed Al Herz, Marry Ellen Conlay, Charlotte Cunningham – Rundles et al. A phenotypic approach for IUIS PID classification and diagnosis. Guidelines for clinicians at the bedside. J Clin. Immunol.2013 August; 33(6): 1078–1087.
2- Sociedad Latinoamericana de inmunodeficiencia. Estadística-Registro de IDPs. Actualizado 23/5/2015. P1-9.
3- Macías C, Sánchez M, Insua C, García MC, Hernández G, Arce A, Merlín JC, Martínez R. Tratamiento con inmunoglobulina G subcutánea en enfermos con inmunodeficiencias primarias: resultados preliminares del estudio multicéntrico cubano. Revista Cubana de Hematología, Inmunología y Hemoterapia. 2016; 32 (3): 1-10.
4- Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999; 93(3):190-7.
5- Etephan Ehl. New clinical diagnosis criteria for the ESID Registry. Geneva: European Society for Immunodeficiencies; 2014. Disponible en: http://esid.org/Working-Parties/Registry/Diagnosis-criteria. [Acceso: 2 de junio de 2016].
6- Sang-Hwa Urm, Hyun Don Yun, Yilma A. Fenta, Kwang Ha Yoo, Roshini S. Abraham, John Hagan, MD, Young J. Juhn. Asthma and Risk of Selective IgA Deficiency or Connnnon Variable Innmunodeficiency: A Population-Based Case-Control Study. Mayo Clin Prcc. August 2013:88(8):813-821 http7/dx.doi.org/10.101é/j,mayocp.2013.05.021 www.mayoctinicproceedings.org
7- Yel L. Selective IgA deficiency. J Clin Immunol 2010; 30 (1):10-6.
8- Rachid R, Castigli E, Geha RS, Bonilla FA. TACI mutation in common variable
9- Immunodeficiency and IgA deficiency. Current Allergy & Asthma Reports. 2006;6:357–362.[PubMed: 16899196]
10- Wang Ning NS, Vyse, Timothy J.; Anand, Vidya; Gunnarson, Iva; Sturfelt, Gunnar; Rantapaa, Solbritt; Elvin, Kerstin; Truedsson, Lennart; Andersson, Bengt A.; Dahle, Charlotte; Ortqvist, Eva; Gregersen, Peter K.; Behrens, Timothy W.; Hammarstrom, Lennart. Selective IgA deficiency in autoimmune diseases. Molecular Medicine. 2011; 17:1383–1396. [PubMed: 21826374].
11- Singh K; Chang C; Gershwin ME. IgA deficiency and autoimmunity. Autoimmun Rev; 2014 Feb 13(2):163-77.
12- Hostoffer R, Stiehm R, Feldweg A. Selective IgA deficiency: clinical manifestations, phatophysiology, and diagnosis. Up To Date. 2012-03.
13- Abul K. Abbas, Andrew H. Lichtman, Shiv Pillai. Inmunología celular y Molecular. Séptima ed.2012.Barcelona España
14- Iznaga E. Masivo uso de la ozonoterapia en hospitales y policlínicos. BVS. http//promocionevento.sld.cu/ozonocuba2015/.
15- Bocci V, Luzzi E, Corradeshi F, Paulesu L, Di Stefano A. Studies on the biological effects of ozone. An attempt to define conditions for optimal induction of cytokines. Lymphokine and Cytokine Res 1993; 12:121-126.
16- Bocci V. Ozonization of blood for the therapy of viral diseases and immunodeficiencies. A hypothesis. Medical hypotesis 1992; 39: 30-34.
17- Bocci V, Borrelli E, Zanardi I, Travagli V. Oxygen-ozone therapy is at a cross-road. Revista Española de Ozonoterapia. 2011; 1(1):74-86.
18- Paulesu L, Luzzi E, Bocci V. Studies on the biological effects of ozone: 2. Induction of tumor necrosis factor (TNF ά) on human leucocytes. Lymphokines Cytokines Res 1991; 10:409-412.
19- BocciV.A., Zanardi lacopo, and Travagli. Ozone acying an human blood yields a hormetic dose-response relations ship.Journal of translational medicine 2011, 9: 66.
20- Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear cells. Toxicol in Vitro. 2005; 19: 55–61.
21- Travagli V, Zanardi I, Silvietti A, Bocci V. Physicochemical investigation on the effects of ozone on blood. Int J Biol Macromol 2007; 41: 504–511.
22- Bocci V, Zanardi I, Travagli V. Oxygen/ozone as a medical gas mixture. A critical evaluation of the various methods clarifies positive and negative aspects. Med Gas Res 2011; 1: 6.
23- Viebahn-Hänsler R, León Fernández OS, Fahmy Z. Ozone in Medicine: The Low-Dose Ozone Concept—Guidelines and Treatment Strategies. Ozone: Science & Engineering: The Journal of the International
Ozone Association 2012, 34(6): 408-424
24- Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharm 2006; 216:493-504.
25- Martinez SG, RE L. Rectal Administration and its Application in ozone therapy. International Journal of ozone therapy. 2012; 11: 41-49.
26- Schwartz A. Hacia un Enfoque Unificado para la Práctica de la ozonoterapia en el Mundo. Revista Española de Ozonoterapia. 2015; 5(1): 1 -1
27- Ronald JH, Giclas PC. Diagnostic Immunology Laboratory Manual. New York, USA: Raven Press; 1991.
28- Locke BA, Dasu T, Verbsky JW. Laboratory Diagnosis of Primary Immunodeficiencies. Clinic Rev Allerg Immunol 2014; 46:154–168
29- Witko-Sarsat V, Friendlander M, Nguyen-Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocytes activation in chronic renal failure. J Immunol 1998; 161:2524-2532.
30- Harma M, Erel O. Increased oxidative stress in patients with hydatidiform mole. Swiss Med Wkly 2003; 133:563-66.
31- Collins AR, Dobson VL, Dusinska M, Kennedy G, Stetina R. The comet assay: what can it really tell us? Mutat Res 1997; 375:183-93.
32- Marklund S, Marklund G. Involvement of superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974; 47:469-74.
33- Aebi H. Catalase in vitro. Meth Enzymol 1984; 105:121.
34- Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70:158-169.
35- Calberg I, Mannervik B. Glutathione reductase. Meth Enzymol 1985; 113:485-90.
36- Sedlak J, Lindasy RH. Estimation of total protein bound and non-protein sulfhydryl group in tissue with Ellman`s reagent. Anal Biochem 1968; 25:192-205.
37- Morón Rodríguez FI, Rodríguez ML. Farmacología General. La Habana. Cuba: Ciencias Médicas; 2002.
38- Calunga JL, Paz Y, Menéndez S, Martínez A, Hernández A, Hernández A. La ozonoterapia en pacientes con enfisema pulmonar. Rev Med Chile 2011; 139: 439-447.
39- Tducusin RJ, Kazu M, Sarashina T, Uzaka Y, Tanabe S, Otan.D Phagocytosis of bovine blood and milk polymorph nuclear leukocyte after ozone gas administration in vitro. J Vet Med Sci 2003; 65(4): 535-539.
40- Díaz J, Sardiñas G, Menéndez S, Macias C. Immumodulatory effect of ozone in children’s with deficiency in the phagocytic activity. Mediciego 2012; 18(1).
41- Hernández FA. To What Extent Does Ozone Therapy Need a Real Biochemical Control System? Assessment and Importance of Oxidative Stress. Archives of Medical Research. 2007; 38: 571-578.
42- Lamberto Re, Gregorio Martínez-Sánchez, Marica Bordicchia Giuseppe Malcangi, Antonella Pocognoli, Miguel Angel Morales-Segura, John Rothchild, Armando Rojas. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. European Journal of Pharmacology. 2014; 742: 158-162.
43- Bocci V, Zanardi I, Travagli V: Potentiality of oxygen-ozone therapy to improve the health of aging people. Curr Aging Sci 2010, 3(3):177-187.
44- Nazarina I, Menéndez S, Rivero J. Ozonoterapia en SIDA. Rev Cubana Invest Biomed 2005;24(1):69-71
45- Hernández Rosales, Calunga JL, FernándezJ, Figueras T, Menéndez S. Ozone Therapy Effects on Blood Biomarkers and Lung Function in Asthma, Archives of Medical Researc. 2005 17: 27-48.
46- Guanche D, Samora Z, Hernández F, et al. Effect of ozone/oxygen mixture on systemic oxidative stress and organic damage. Toxicol Mech Methods. 2010 Jan; 20(1):25-30.
